Home / Pharmaceuticals / Peptic Ulcer Drugs Market By Drug Class (Antibiotics, Proton Pump Inhibitors (PPLS), H2 Receptor Antagonists, Gastric Mucosal Protective Drugs, Antacids, Prostaglandin Agonists) - Growth, Share, Opportunities & Competitive Analysis, 2015 – 2025

Peptic Ulcer Drugs Market By Drug Class (Antibiotics, Proton Pump Inhibitors (PPLS), H2 Receptor Antagonists, Gastric Mucosal Protective Drugs, Antacids, Prostaglandin Agonists) - Growth, Share, Opportunities & Competitive Analysis, 2015 – 2025

Published: Aug 2017 | Report Code: 58606-08-17

A peptic ulcer is forms of painful sores that develops on the mucosal lining of the stomach, small intestine or lower esophagus. Increase in prevalence of H. Pylori infection, improved diagnostic techniques, easy availability of treatment medication, preferable use of peptic ulcer medication over surgery, increase in rate of smocking and over use of NSAIDs are driving the growth of peptic ulcer drugs market globally.

The report titled “Peptic Ulcer Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall peptic ulcer drugs market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on drug class and different geographical regions.  Geographically, the global peptic ulcer drugs market is studied for the following regional markets:   

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of MEA

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global peptic ulcer drugs market. In depth analysis of pipeline molecule for key products in peptic ulcer treatment, global epidemiology data for peptic ulcer have been included in report. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global peptic ulcer drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global peptic ulcer drugs market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.      

Thus, the research study provides a holistic view of the global peptic ulcer drugs market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.   

Peptic Ulcer Drugs Market

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Peptic Ulcer Drugs Market Snapshot
2.2 Global Peptic Ulcer Drugs Market, Drug Class
2.3 Global Peptic Ulcer Drugs Market Share, by Geography, 2016 (Value %)

Chapter 3 Peptic Ulcer Drugs Market Analysis
3.1 Global Peptic Ulcer Drugs Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis in Peptic Ulcer Drugs Market
3.4 Global Epidemiology Data for Peptic Ulcer
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Peptic Ulcer Drugs Market

Chapter 4 Global Peptic Ulcer Drugs Market, by Drug Class
4.1 Overview
4.2 Top 3 Countries
4.3 Antibiotics
4.4 Proton Pump Inhibitors (PPIs)
4.5 H2 Receptor Antagonists
4.6 Gastric Mucosal Protective Drugs
4.7 Antacids
4.8 Prostaglandin Agonists

Chapter 5 Global Peptic Ulcer Drugs Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Peptic Ulcer Drugs Market, by Drug Class, 2015- 2025 (US$)
5.2.2 North America Peptic Ulcer Drugs Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Peptic Ulcer Drugs Market, by Drug Class, 2015- 2025 (US$)
5.3.2 Europe Peptic Ulcer Drugs Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Peptic Ulcer Drugs Market, by Drug Class, 2015- 2025 (US$)
5.4.1 Asia Pacific Peptic Ulcer Drugs Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Peptic Ulcer Drugs Market, by Drug Class, 2015- 2025 (US$)
5.5.2 Latin America Peptic Ulcer Drugs Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Peptic Ulcer Drugs Market, by Drug Class, 2015- 2025 (US$)
5.6.2 Middle East and Africa Peptic Ulcer Drugs Market, by Country, 2015- 2025 (US$)

Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.2 AstraZeneca plc.
6.3 Cadila Healthcare Ltd.
6.4 Daewoong Pharmaceuticals
6.5 Eisai Co. Ltd.
6.6 PharmaKing Co. Ltd.
6.7 Taiho Pharmaceutical (A Otsuka Holdings)
6.8 Takeda Pharmaceutical
6.9 Yuhan Corporation

List Of Table :

TABLE 1 Market Positioning of Key Players in Global Peptic Ulcer Drugs Market
TABLE 2 Global Peptic Ulcer Drugs Market, by Drug Class, 2015 – 2025 (US$ Bn)
TABLE 3 Top 3 Countries in Global Peptic Ulcer Drugs Market, 2015 – 2025 (US$ Bn)
TABLE 4 Global Peptic Ulcer Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 5 North America Peptic Ulcer Drugs Market, by Drug Class, 2015-2025 (US$ Bn)
TABLE 6 North America Peptic Ulcer Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 7 Europe Peptic Ulcer Drugs Market, by Drug Class, 2015-2025 (US$ Bn)
TABLE 8 Europe Peptic Ulcer Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 9 Asia Pacific Peptic Ulcer Drugs Market, by Drug Class, 2015-2025 (US$ Bn)
TABLE 10 Asia Pacific Peptic Ulcer Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 11 Latin America Peptic Ulcer Drugs Market, by Drug Class, 2015-2025 (US$ Bn)
TABLE 12 Latin America Peptic Ulcer Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 13 Middle East and Africa Peptic Ulcer Drugs Market, by Drug Class, 2015-2025 (US$ Bn)
TABLE 14 Middle East and Africa Peptic Ulcer Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 15 Abbott Laboratories: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 AstraZeneca plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 Cadila Healthcare Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 Daewoong Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 Eisai Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 20 PharmaKing Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 Taiho Pharmaceutical (A Otsuka Holdings): Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 Takeda Pharmaceutical: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Yuhan Corporation: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

List Of Figures :

FIG. 1 Peptic Ulcer Drugs Market: Research Methodology
FIG. 2 Global Peptic Ulcer Drugs Market, by Drug Class, 2016 (US$ Bn)
FIG. 3 Global Peptic Ulcer Drugs Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Peptic Ulcer Drugs Market, by Geography, 2016
FIG. 5 Global Antibiotics Market in Peptic Ulcer Treatment, 2015 – 2025 (US$ Bn)
FIG. 6 Global Proton Pump Inhibitors (PPIs) Market in Peptic Ulcer Treatment, 2015 – 2025 (US$ Bn)
FIG. 7 Global H2 Receptor Antagonists Market in Peptic Ulcer Treatment, 2015 – 2025 (US$ Bn)
FIG. 8 Global Gastric Mucosal Protective Drugs Market in Peptic Ulcer Treatment, 2015 – 2025 (US$ Bn)
FIG. 9 Global Antacids Market in Peptic Ulcer Treatment, 2015 – 2025 (US$ Bn)
FIG. 10 Global Prostaglandin Agonists Market in Peptic Ulcer Treatment, 2015 – 2025 (US$ Bn)

Based on drug class, the global peptic ulcer drugs market is segmented as follows:

  • Antibiotics
  • Proton Pump Inhibitors (PPIs)
  • H2 Receptor Antagonists
  • Gastric Mucosal Protective Drugs
  • Antacids
  • Prostaglandin Agonists

Peptic ulcers are forms of painful sores that develops on the mucosal lining of the stomach, small intestine or lower esophagus. Some factors such as increase in incidence of H. pylori infections, change in lifestyles such as stress and diet pattern, increasing smoking rate, overuse of NSAIDs such as Naproxen, Ibuprofen, Aspirin, and Ketoprofen, improve diagnostics techniques and preferable used of medication over the surgeries are driving the growth of peptic ulcer drugs market globally. For the purpose of the study, the peptic ulcer drugs market is segmented on the basis of drug class such as antibiotics, proton pump inhibitors (PPIs), H2 receptor antagonists, gastric mucosal protective drugs, antacids and prostaglandin agonists. It is studied that, in the base year 2016, PPIs were major revenue generating segment because these drugs are preferably prescribed in market for treatment of peptic ulcers caused by H. pylori bacterial infection and NSAIDs. PPIs reduce the amount of acid by blocking the action of the parts of cells that produce acid and prevent further damage.

Peptic Ulcer Drugs Market

For the purpose of this study, the global peptic ulcer drugs market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Peptic Ulcer Drugs Market

It is studied that, in the base year 2016, North America dominated the peptic ulcer drugs market in terms of revenue and it is anticipated that it will show steady growth during forecast period of 2017-2025. Factors such as large number of affected population, higher cost of treatment medication, improved diagnostic technique and upsurge in funding by the government agencies in healthcare system are driving the growth of peptic ulcer drugs market in North America. According to Centers for Disease Control and Prevention (CDC) peptic ulcer is a common illness that affects more than 6 million population in the United States annually. It is observed that currently, Europe is the second largest revenue generating regional market for peptic ulcer drugs due to higher number of affected population, improved diagnostics technique, high healthcare awareness and overuse of pain medication are driving the market growth in Europe. U.K., Germany and France are major revenue contributing countries in Europe. It is anticipated that Asia Pacific will show highest growth rate during the forecast period due to populous countries, developing economic condition and improving healthcare infrastructure would contribute the market growth in Asia Pacific during forecast period.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients